Doctors Question Evidence Behind Pentagon’s Mandatory Testosterone Screening Plan for US Troops
By Mayson WoodbridgeSCN
WASHINGTON — A new Pentagon plan requiring annual testosterone-deficiency screening for U.S. military personnel aged 30 and older is drawing scrutiny from medical experts, who question whether there is enough scientific evidence to justify widespread testing of otherwise healthy service members.
U.S. Defense Secretary Pete Hegseth announced the initiative this week, presenting testosterone screening as part of an effort to improve military readiness, resilience and performance. The program will cover active-duty and reserve personnel aged 30 and above, while younger service members may opt to be tested.
But several doctors and researchers interviewed by Reuters questioned the medical basis for universal screening. Five of six experts consulted by the news agency raised concerns that large-scale testing could lead to unnecessary testosterone treatment, particularly when low laboratory readings are found in people who do not have symptoms of testosterone deficiency.
Testosterone levels can fluctuate depending on factors including sleep, stress, physical activity and the time of day, making interpretation more complicated than simply identifying a single low reading. Critics argue that established medical approaches generally focus on patients who have relevant symptoms combined with repeatedly confirmed low testosterone levels rather than routinely screening entire healthy populations.
Medical experts also warn that unnecessary testosterone therapy can carry risks. Potential concerns include reduced fertility and disruption of the body's natural hormone production, while appropriate diagnosis and medical monitoring remain important for patients receiving treatment.
The Pentagon initiative nevertheless has supporters who argue that broader testing could identify previously undiagnosed hormone deficiencies and provide useful information about the health of the military population.
The debate also comes as the Trump administration considers broader changes surrounding access to testosterone treatment. Recent evidence has eased some earlier concerns about major cardiovascular risks for appropriately selected patients, but specialists continue to emphasize that testosterone therapy should be based on clinical need rather than used automatically as a general performance-enhancement strategy.
The Pentagon has so far provided limited public detail about precisely how abnormal results will be evaluated, what diagnostic thresholds will be used or under what circumstances treatment will be recommended.
The central question is therefore not whether testosterone deficiency can be a legitimate medical condition — it can — but whether testing every service member over a certain age is an evidence-based way to improve the fighting force.
As implementation moves forward, the Pentagon could face increasing pressure to demonstrate that its new program improves military health and readiness without encouraging unnecessary diagnosis or treatment.
Most Unique Fact
Five of six medical experts interviewed by Reuters questioned or expressed concerns about the Pentagon's broad screening approach, warning that widespread testing could potentially lead to unnecessary testosterone treatment among otherwise healthy troops.